Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Lung Cancer | Research

Cuproptosis-related ceRNA axis triggers cell proliferation and cell cycle through CBX2 in lung adenocarcinoma

Authors: Jiang Wu, Guang Fu, Chao Luo, Liang Chen, Quanxing Liu

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Lung adenocarcinoma (LUAD) has high morbidity and mortality. Despite substantial advances in treatment, the prognosis of patients with LUAD remains unfavorable. The ceRNA axis has been reported to play an important role in the pathogenesis of LUAD. In addition, cuproptosis is considered an important factor in tumorigenesis. The expression of CBX2 has been associated with the development of multiple tumors, including LUAD. However, the precise molecular mechanisms through which the cuproptosis-related ceRNA network regulates CBX2 remain unclear.

Methods

The DEGs between tumor and normal samples of LUAD were identified in TCGA database. The “ConsensusClusterPlus” R package was used to perform consensus clustering based on the mRNA expression matrix and cuproptosis-related gene expression profile. Then, LASSO-COX regression analysis was performed to identify potential prognostic biomarkers associated with cuproptosis, and the ceRNA network was constructed. Finally, the mechanisms of ceRNA in LUAD was studied by cell experiments.

Results

In this study, the AC144450.1/miR-424-5p axis was found to promote the progression of LUAD by acting on CBX2. The expression of AC144450.1 and miR-424-5p can be altered to regulate CBX2 and is correlated with cell proliferation and cell cycle of LUAD. Mechanistically, AC144450.1 affects the expression of CBX2 by acting as the ceRNA of miR-424-5p. In addition, a cuproptosis-related model were constructed in this study to predict the prognosis of LUAD.

Conclusions

This study is the first to demonstrate that the AC144450.1/miR-424-5p/CBX2 axis is involved in LUAD progression and may serve as a novel target for its diagnosis and treatment.
Appendix
Available only for authorised users
Literature
1.
Rudin CM, Brambilla E, Faivre-Finn C, Sage JJNRDP. Small-cell lung cancer. 2021;7:3.
2.
Myers DJ, Wallen JM. Lung adenocarcinoma. StatPearls. StatPearls Publishing; 2022.
3.
Kazdal D, Hofman V, Christopoulos P, Ilié M, Stenzinger A, Hofman PJG, Chromosomes et al. Fusion-positive non‐small cell lung carcinoma: biological principles, clinical practice, and diagnostic implications. 2022;61:244–60.
4.
Bennett CW, Berchem G, Kim YJ, El-Khoury VJO. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. 2016;7:71013.
5.
Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M et al. Early detection of cancer. 2022;375:eaay9040.
6.
Nooreldeen R, Bach HJI. Current and future development in lung cancer diagnosis. 2021;22:8661.
7.
Statello L, Guo C-J, Chen L-L. Huarte MJNrMcb. Gene regulation by long non-coding RNAs and its biological functions. 2021;22:96–118.
8.
Chen Y, Gao D-Y, Huang LJA. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. 2015;81:128–41.
9.
Lee SS, Cheah YKJJ. The interplay between microRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression. 2019;2019.
10.
Guo C, Ju Q-q, Zhang C-x, Gong M, Li Z-l. Gao Y-yJBc. Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia. 2020;20:1–12.
11.
Zhang M, Zeng J, Zhao Z, Liu ZJM. Loss of MiR-424‐3p, not miR‐424‐5p, confers chemoresistance through targeting YAP1 in non‐small cell lung cancer. 2017;56:821–32.
12.
Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. 2019;20:5573.
13.
Briata P, Gherzi RJN-cR. Long non-coding RNA-ribonucleoprotein networks in the post-transcriptional control of gene expression. 2020;6:40.
14.
Li Z, Zhao W, Wang M, Zhou XJGEPC. The role of long noncoding RNAs in gene expression regulation. 2019:1–17.
15.
Wu X, Sui Z, Zhang H, Wang Y, Yu ZJFO. Integrated Analysis of lncRNA–Mediated ceRNA network in lung adenocarcinoma. 2020;10:554759.
16.
Tiansheng G, Junming H, Xiaoyun W, Peixi C, Shaoshan D, Qianping CJCJ. lncRNA metastasis-associated lung adenocarcinoma transcript 1 promotes proliferation and invasion of non-small cell lung cancer cells via down-regulating miR-202 expression. 2020;22:375.
17.
Liu W, Yin N-C, Liu H, Nan K-JJG. Cav-1 promote lung cancer cell proliferation and invasion through lncRNA HOTAIR. 2018;641:335–40.
18.
Zhu H, Zhou Y, Wang Q, Yang X, Ding C, Xiong YJB et al. Long non-coding RNA LALTOP promotes non-small cell lung cancer progression by stabilizing topoisomerase IIα mRNA. 2021;574:56–62.
19.
Bai Q, Pan Z, Nabi G, Rashid F, Liu Y, Khan SJAJCR. Emerging role of competing endogenous RNA and associated noncoding RNAs in thyroid cancer. 2022;12:961.
20.
Zhang Z, Cheng J, Wu Y, Qiu J, Sun Y, Tong XJM. LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer. 2016;14:2465–72.
21.
Sui J, Li Y-H, Zhang Y-Q, Li C-Y, Shen X, Yao W-Z et al. Integrated analysis of long non-coding RNA–associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. 2016;49:2023–36.
22.
Vecera M, Sana J, Lipina R, Smrcka M, Slaby OJI. Long non-coding RNAs in gliomas: from molecular pathology to diagnostic biomarkers and therapeutic targets. 2018;19:2754.
23.
Xie J, Yang Y, Gao Y, He JJMC. Cuproptosis: mechanisms and links with cancers. 2023;22:46.
24.
Chi H, Peng G, Wang R, Yang F, Xie X, Zhang J et al. Cuprotosis programmed-cell-death-related lncRNA signature predicts prognosis and immune landscape in PAAD patients. 2022;11:3436.
25.
Liu T, Cai L, Hua H, Jiang X, Xu X, Zhang T et al. Cuprotosis patterns are associated with tumor mutation burden and immune landscape in lung adenocarcinoma2022; 2022.
26.
Sha S, Si L, Wu X, Chen Y, Xiong H, Xu Y et al. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer. 2022;13:922780.
27.
Zhao Q, Qi TJFO. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression. 2023;13:1117164.
28.
Ma S, Zhu J, Wang M, Zhu J, Wang W, Xiong Y et al. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. 2022;11:2079.
29.
Zhang P, Pei S, Liu J, Zhang X, Feng Y, Gong Z et al. Cuproptosis-related lncRNA signatures: Predicting prognosis and evaluating the tumor immune microenvironment in lung adenocarcinoma. 2023;12:1088931.
30.
Zhang H, Shi Y, Yi Q, Wang C, Xia Q, Zhang Y et al. A novel defined cuproptosis-related gene signature for predicting the prognosis of lung adenocarcinoma. 2022;13:975185.
31.
Kim JJ, Kingston REJNRG. Context-specific polycomb mechanisms in development. 2022;23:680–95.
32.
Morey L, Santanach A, Blanco E, Aloia L, Nora EP, Bruneau BG et al. Polycomb regulates mesoderm cell fate-specification in embryonic stem cells through activation and repression mechanisms. 2015;17:300–15.
33.
Kiani S, Akhavan-Niaki H, Fattahi S, Kavoosian S, Jelodar NB, Bagheri N et al. Purified sulforaphane from broccoli (Brassica oleracea var. italica) leads to alterations of CDX1 and CDX2 expression and changes in miR-9 and miR-326 levels in human gastric cancer cells. 2018;678:115–23.
34.
Zheng S, Lv P, Su J, Miao K, Xu H, Li MJA. Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K/AKT signaling pathway. 2019;11:1668.
35.
Hu F-F, Chen H, Duan Y, Lan B, Liu C-J, Hu H et al. CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma. 2022;27:670–84.
36.
Weng W, Wei Q, Toden S, Yoshida K, Nagasaka T, Fujiwara T et al. Circular RNA ciRS-7—a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. 2017;23:3918–28.
37.
Chen W, Zhao W, Zhang L, Wang L, Wang J, Wan Z et al. MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via wnt signaling pathway. 2017;8:94317.
38.
Dong X, Shao C, Tu J, Chen D, Xu S. Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung Adenocarcinoma. 2023.
39.
40.
Ma S, Zhu J, Wang M, Zhu J, Wang W, Xiong Y, et al. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Transl Lung Cancer Res. 2022;11:2079–93.CrossRefPubMedPubMedCentral
41.
Li Q, Wang T, Zhou Y, Shi J. Cuproptosis in lung cancer: mechanisms and therapeutic potential. Mol Cell Biochem. 2023.
42.
43.
Chen Y, Chen X, Wang XJFC, Biology D. Identification of a prognostic model using cuproptosis-related genes in uveal melanoma. 2022;10:973073.
44.
Jiang G, Song C, Wang X, Xu Y, Li H, He Z et al. The multi-omics analysis identifies a novel cuproptosis-anoikis-related gene signature in prognosis and immune infiltration characterization of lung adenocarcinoma. 2023;9.
45.
Wang Y, Zhang C, Ji C, Jin W, He X, Yu S et al. Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma. 2022;13:1006938.
46.
Ling X, Zhang L, Fang C, Liang H, Zhu J, Ma JJTLCR. Development of a cuproptosis-related signature for prognosis prediction in lung adenocarcinoma based on WGCNA. 2023;12:754.
47.
Wang L, Ren B, Zhuang H, Zhong Y, Nan YJTiCR. Treatment. CBX2 induces glioma cell proliferation and invasion through the Akt/PI3K pathway. 2021;20:15330338211045831.
48.
Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA et al. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. 2018;7:92.
49.
Chen WY, Zhang XY, Liu T, Liu Y, Zhao YS, Pang DJO. Chromobox homolog 2 protein: a novel biomarker for predicting prognosis and taxol sensitivity in patients with breast cancer. 2017;13:1149–56.
50.
Entezari M, Taheriazam A, Paskeh MDA, Sabouni E, Zandieh MA, Aboutalebi M et al. The pharmacological and biological importance of EZH2 signaling in lung cancer. 2023;160:114313.
51.
Yan Y, Lu Y, Mao K, Zhang M, Liu H, Zhou Q et al. Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis. 2019;13:618–30.
52.
Gu X, Li H, Sha L, Zhao WJBRI. Construction and comprehensive analyses of a competing endogenous RNA network in tumor-node-metastasis stage I hepatocellular carcinoma. 2020;2020.
Metadata
Title
Cuproptosis-related ceRNA axis triggers cell proliferation and cell cycle through CBX2 in lung adenocarcinoma
Authors
Jiang Wu
Guang Fu
Chao Luo
Liang Chen
Quanxing Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02887-0

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue

Research

The clinical characteristics of non-cystic fibrosis bronchiectasis patients with positive serum tumor markers: a retrospective study

Research

The role of colchicine in the management of COVID-19: a Meta-analysis

Study Protocol

A prospective, open-label, randomized clinical trial to evaluate the efficacy and safety of remimazolam in patients undergoing EBUS-TBNA: REST trial design

Research

Value of preoperative evaluation of FEV1 in patients with destroyed lung undergoing pneumonectomy - a 20-year real-world study

Research

Four different models for simulation-based training of bronchoscopic procedures

Research

Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits